Ocular FIP treatment enters a more practical antiviral era

CURRENT FULL VERSION: Ocular FIP is moving from a largely hopeless diagnosis to a treatable, though still complex, clinical presentation, and that’s the core takeaway behind VETgirl’s recent discussion of antiviral therapy for feline infectious peritonitis. The podcast centers on a 2025 Journal of Veterinary Internal Medicine case series from the Royal Veterinary College evaluating remdesivir, GS-441524, or both in cats with ocular FIP, and it frames a presentation that can include vision changes, ocular inflammation, and a guarded prognosis. Clinically, these are the cats with anterior chamber findings such as keratic precipitates, iris color change, dyschoria or anisocoria, hyphema, hypopyon, or fibrinous exudate, as well as posterior segment lesions including tapetal or non-tapetal retinal changes, hemorrhage, vascular tortuosity, retinal detachment, or perivascular cuffing. In some patients, the eye findings are unilateral or bilateral and may be the first clue to underlying systemic disease. (cliniciansbrief.com)

That change has been building for several years. FIP was long regarded as almost uniformly fatal, but published clinical experience with antiviral therapy has steadily expanded, first through research and informal access pathways, then through more structured prescribing routes. VETgirl’s broader FIP review notes that antivirals have “flipped the script” on the disease, with reported response rates now reaching roughly 85% to 90% in some discussions of real-world practice. In the U.S., a major inflection point came when FDA announced it did not intend to enforce new animal drug approval requirements for compounded GS-441524 prescribed by veterinarians for specific cats with FIP under the conditions in GFI #256. Cornell then reported that a compounded oral formulation became available in the U.S. on June 1, 2024, giving clinicians and pet parents a legal pharmacy-based route that had not previously existed. (fda.gov)

The clinical nuance is that ocular FIP is not just “regular FIP with eye signs.” VETgirl’s ocular episode underscores that ocular and neurologic involvement are seen much more often in the non-effusive form than in wet FIP, and that some cats present with an ocular-signs-dominant form in which uveitis is the primary feature. Published reviews and clinical summaries consistently note that cats with ocular or neurologic disease often require higher dosing than cats with uncomplicated effusive disease, in part because drug penetration into the eye and central nervous system is more challenging. A 2025 Scientific Reports analysis of cats treated with GS-441524 from 2020 to 2024 concluded that, at sufficient dosage, GS-441524 was a viable option for surviving cats with ocular and/or neurologic FIP. Clinician-facing reviews have made the same point, warning that dose selection and escalation matter when eye involvement is present. (nature.com)

At the same time, enthusiasm about shorter treatment courses needs context. A 2025 BSAVA paper on high-dose induction and treatment cessation criteria found that some cats could complete treatment in a median of 57 days without recurrence, but the study excluded cats with only ocular or neurologic signs. Likewise, a study comparing 42-day and 84-day oral GS-441524 treatment focused on cats with effusive FIP, not isolated ocular disease. VETgirl’s podcast on dosing and duration adds an important practical point: many cats look better within about the first week of therapy, but early appetite and weight gain do not necessarily mean the virus has been cleared, particularly from harder-to-penetrate tissues such as the eyes and CNS. That is why investigators have been looking beyond subjective improvement to objective treatment-stop criteria, including trends in serum amyloid A, alpha-1 acid glycoprotein, and the albumin:globulin ratio. Worms & Germs, in reviewing the shorter-course literature, explicitly cautioned against broadly applying those findings to non-ocular and especially ocular or neurologic cases. In other words, the field is advancing, but the evidence for abbreviated therapy is still narrower than some headlines might suggest. (pubmed.ncbi.nlm.nih.gov)

Industry and expert commentary has reflected both optimism and caution. Cornell described legal U.S. access to compounded GS-441524 as a “significant ray of hope,” while FDA emphasized that compounded GS-441524 products remain unapproved, even as the agency exercises enforcement discretion under defined conditions. Meanwhile, quality-control concerns haven’t disappeared: an AJVR study evaluating unregulated antiviral products found that while sampled GS-441524 vials generally did contain GS-441524, concentrations sometimes differed from the label, and products sold as GC376 did not actually contain GC376 in that analysis. For veterinarians, that reinforces the value of using reputable, regulated compounding channels where available. The same practical caution comes through in podcast discussions aimed at clinicians: treatment advances are real, but diagnosis, drug selection, and follow-up still require disciplined case management rather than social-media-era shortcuts. (vet.cornell.edu)

Why it matters: For general practitioners, feline-only clinicians, ophthalmology services, and emergency teams, ocular FIP now demands a different workflow. The challenge is no longer only recognizing FIP on the differential list, but also moving quickly enough to diagnose, discuss treatment access, choose an initial antiviral plan, and monitor response. Ocular cases may improve dramatically, but they can also require more individualized dosing, serial ophthalmic assessment, and careful interpretation of clinicopathologic markers. They’re also the kind of cases where pet parent expectations need especially clear framing: treatment is increasingly possible, but not every protocol validated in effusive FIP can be copied over without adjustment. More broadly, recent clinician education has emphasized that presumptive diagnosis in practice still hinges on assembling signalment, effusion characteristics, inflammatory markers, imaging, ocular or neurologic findings, and other compatible clues rather than waiting for a perfect single test result. (cliniciansbrief.com)

What to watch: The next phase will likely focus on protocol refinement rather than proof of concept, including better guidance for ocular and neurologic dosing, biomarker-guided treatment duration, therapeutic drug monitoring, and more formal consensus recommendations as legal access expands and more real-world outcome data accumulate. Just as important, expect continued discussion of practical diagnostic algorithms and stopping rules that help clinicians decide not only how to start therapy, but when it is truly safe to stop. (pubmed.ncbi.nlm.nih.gov)